| Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel JW Suh, BK Koo, SY Zhang, KW Park, JY Cho, IJ Jang, DS Lee, DW Sohn, ... Cmaj 174 (12), 1715-1722, 2006 | 299 | 2006 |
| Pharmacokinetics of Hydroxychloroquine and Its Clinical Implications in Chemoprophylaxis against Malaria Caused by Plasmodium vivax HS Lim, JS Im, JY Cho, KS Bae, TA Klein, JS Yeom, TS Kim, JS Choi, ... Antimicrobial agents and chemotherapy 53 (4), 1468-1475, 2009 | 211 | 2009 |
| Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers JY Chung, JY Cho, KS Yu, JR Kim, DS Oh, HR Jung, KS Lim, KH Moon, ... Clinical Pharmacology & Therapeutics 78 (4), 342-350, 2005 | 203 | 2005 |
| Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers SY Jun, IJ Jang, S Yoon, K Jang, KS Yu, JY Cho, MW Seong, GM Jung, ... Antimicrobial agents and chemotherapy 61 (6), 10.1128/aac. 02629-16, 2017 | 161 | 2017 |
| MRP2 haplotypes confer differential susceptibility to toxic liver injury JH Choi, BM Ahn, J Yi, JH Lee, JH Lee, SW Nam, CY Chon, KH Han, ... Pharmacogenetics and genomics 17 (6), 403-415, 2007 | 159 | 2007 |
| A variant 2677A allele of the MDR1 gene affects fexofenadine disposition SY Yi, KS Hong, HS Lim, JY Chung, DS Oh, JR Kim, HR Jung, JY Cho, ... Clinical Pharmacology & Therapeutics 76 (5), 418-427, 2004 | 154 | 2004 |
| Influence of OATP1B1 Genotype on the Pharmacokinetics of Rosuvastatin in Koreans JH Choi, MG Lee, JY Cho, JE Lee, KH Kim, K Park Clinical Pharmacology & Therapeutics 83 (2), 251-257, 2008 | 149 | 2008 |
| Effect of the UGT2B15 Genotype on the Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Intravenous Lorazepam in Healthy Volunteers JY Chung, JY Cho, KS Yu, JR Kim, HR Jung, KS Lim, IJ Jang, SG Shin Clinical Pharmacology & Therapeutics 77 (6), 486-494, 2005 | 127 | 2005 |
| Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance KH Shin, MH Choi, KS Lim, KS Yu, IJ Jang, JY Cho Clinical pharmacology & therapeutics 94 (5), 601-609, 2013 | 120 | 2013 |
| Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers SH Lee, BH Kim, WS Nam, SH Yoon, JY Cho, SG Shin, IJ Jang, KS Yu The Journal of Clinical Pharmacology 52 (2), 195-203, 2012 | 118 | 2012 |
| Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states KS Yu, JY Cho, IJ Jang, KS Hong, JY Chung, JR Kim, HS Lim, DS Oh, ... Clinical Pharmacology & Therapeutics 76 (2), 104-112, 2004 | 118 | 2004 |
| Antihyperglycemic mechanism of metformin occurs via the AMPK/LXRα/POMC pathway K Cho, JY Chung, SK Cho, HW Shin, IJ Jang, JW Park, KS Yu, JY Cho Scientific reports 5 (1), 8145, 2015 | 111 | 2015 |
| Indoxyl sulfate (IS)-mediated immune dysfunction provokes endothelial damage in patients with end-stage renal disease (ESRD) HY Kim, TH Yoo, Y Hwang, GH Lee, B Kim, J Jang, HT Yu, MC Kim, ... Scientific reports 7 (1), 3057, 2017 | 108 | 2017 |
| Pharmacokinetic and Pharmacodynamic Interaction of Lorazepam and Valproic Acid in Relation to UGT2B7 Genetic Polymorphism in Healthy Subjects JY Chung, JY Cho, KS Yu, JR Kim, KS Lim, DR Sohn, SG Shin, IJ Jang Clinical pharmacology & therapeutics 83 (4), 595-600, 2008 | 108 | 2008 |
| Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19 KS Yu, DS Yim, JY Cho, SS Park, JY Park, KH Lee, IJ Jang, SY Yi, KS Bae, ... Clinical Pharmacology & Therapeutics 69 (4), 266-273, 2001 | 107 | 2001 |
| Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy DW Kim, SK Lee, K Chu, IJ Jang, KS Yu, JY Cho, SJ Kim Epilepsy research 84 (1), 86-90, 2009 | 96 | 2009 |
| GM-CSF induces inflammatory macrophages by regulating glycolysis and lipid metabolism YR Na, GJ Gu, D Jung, YW Kim, J Na, JS Woo, JY Cho, H Youn, SH Seok The Journal of Immunology 197 (10), 4101-4109, 2016 | 91 | 2016 |
| Apple juice greatly reduces systemic exposure to atenolol H Jeon, IJ Jang, SH Lee, K Ohashi, T Kotegawa, I Ieiri, JY Cho, SH Yoon, ... British journal of clinical pharmacology 75 (1), 172-179, 2013 | 88 | 2013 |
| Molecular mechanism for alkyl sulfide-modulated carbon tetrachloride-induced hepatotoxicity: the role of cytochrome P450 2E1, P450 2B and glutathione S-transferase expression. SG Kim, HC Chung, JY Cho Journal of Pharmacology and Experimental Therapeutics 277 (2), 1058-1066, 1996 | 87 | 1996 |
| Lithocholic acid disrupts phospholipid and sphingolipid homeostasis leading to cholestasis in mice T Matsubara, N Tanaka, AD Patterson, JY Cho, KW Krausz, FJ Gonzalez Hepatology 53 (4), 1282-1293, 2011 | 86 | 2011 |
